Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Instruments, Reagents, Services), By Technology (Immunoassays, POC, Molecular Diagnostics), By End user (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition 2020-2030F

Market Overview

Global Helicobacter Pylori Diagnostics Market was valued at USD 580.75 Million in 2024 and is anticipated to project study growth in the forecast period with a CAGR of 4.30% through 2030. The Helicobacter Pylori (H. pylori) diagnostics market has witnessed significant growth in recent years due to the rising prevalence of H. pylori infections and the increasing awareness about its role in various gastrointestinal diseases, including peptic ulcers and gastric cancer. Helicobacter pylori is a spiral-shaped bacterium that infects the stomach lining and is a common pathogen responsible for various digestive disorders. The infection is primarily transmitted through oral-oral or fecal-oral routes and is associated with gastritis, peptic ulcers, and in severe cases, stomach cancer. Timely and accurate diagnosis is crucial for the effective management of H. pylori-related conditions, driving the demand for advanced diagnostic methods.

The global H. pylori diagnostics market is experiencing growth due to the high prevalence of H. pylori infections worldwide. Emerging economies, in particular, are witnessing a surge in cases, creating a substantial market demand. Non-invasive diagnostic methods such as urea breath tests and stool antigen tests are gaining popularity due to their ease of use and patient comfort. These methods are gradually replacing invasive procedures like endoscopy. Advances in diagnostic technologies, such as molecular diagnostics and serology, are enhancing the accuracy and speed of H. pylori detection. These developments are positively impacting the market by providing more reliable results. The demand for point-of-care testing (POCT) devices is increasing, as they offer rapid and on-the-spot results. These devices are particularly beneficial in primary care settings and resource-limited areas.

The global Helicobacter Pylori diagnostics market is set to expand in the coming years, driven by factors such as high infection rates, technological advancements, and the increasing demand for non-invasive testing. However, the market is not without its challenges, including the high cost of diagnostic tools and antibiotic resistance. To capitalize on the opportunities and address the challenges, stakeholders must focus on innovation, collaboration, and patient education to ensure early diagnosis and effective management of H. pylori-related diseases. As the global healthcare landscape continues to evolve, the H. pylori diagnostics market is positioned for sustained growth and development.

Key Market Drivers

Rising Prevalence of Helicobacter Pylori Infections is Driving the Global Helicobacter Pylori Diagnostics Market

Helicobacter pylori, a spiral-shaped bacterium that infects the human stomach lining, has been recognized as a major global health concern. This microorganism is a primary cause of various gastrointestinal diseases, including peptic ulcers and gastric cancers. The rising prevalence of Helicobacter pylori infections is pushing the global Helicobacter pylori diagnostics market to new heights. Helicobacter pylori infections affect a substantial portion of the global population, with prevalence varying by region. It is estimated that over half of the world's population may be infected with H. pylori. Developing countries often have higher infection rates due to poorer sanitation and healthcare access. According to the World Health Organization (WHO), approximately 1.5 million people globally die from diarrheal diseases each year, with children under the age of five in developing countries being particularly vulnerable. These children face a range of health issues, from diarrhoea and vomiting to malnutrition and, in severe cases, death. In addition to the pathogens responsible for diarrheal diseases, one of the most significant gastrointestinal pathogens is Helicobacter pylori, which contributes to a variety of serious digestive conditions.

H. pylori infection is responsible for 95% of duodenal ulcers and 70% of gastric ulcers. The progression of this infection to atrophic gastritis, and eventually to stomach cancer, is commonly linked to pangastritis, a condition characterized by inflammation of both the upper and lower regions of the stomach. In some cases, untreated infections can lead to severe complications, such as gastrointestinal bleeding and perforation. Perhaps the most concerning consequence of Helicobacter pylori infection is its association with gastric cancer. Long-term infection significantly increases the risk of developing stomach cancer, making it a leading cause of cancer-related deaths worldwide.

The rising prevalence of Helicobacter pylori infections has substantial implications for the global diagnostics market. The global prevalence of Helicobacter pylori infection is approximately 50%, with rates reaching 80%–90% in developing countries and around 35%–40% in the United States. Around 20% of individuals infected with H. pylori experience complications associated with the infection. The surge in Helicobacter pylori infections necessitates more testing to identify individuals at risk. This has boosted the demand for diagnostic tests, including serology, stool antigen tests, and urea breath tests. The growing need for accurate and reliable diagnostics has led to innovations in diagnostic technologies. Molecular testing methods, such as polymerase chain reaction (PCR), have become more widely adopted for their higher sensitivity and specificity. The increasing prevalence of Helicobacter pylori infections and the need for early detection have expanded the global Helicobacter pylori diagnostics market. This has attracted various diagnostic companies and investors to invest in research and development, further driving market growth. Improved healthcare infrastructure and increased awareness about the consequences of Helicobacter pylori infections have also fueled the demand for diagnostics. This, in turn, has made testing more accessible to individuals at risk.

Increased Awareness and Screening Programs is Driving the Global Helicobacter Pylori Diagnostics Market

The increasing recognition of the health hazards linked to H. pylori infections is a major factor propelling the worldwide Helicobacter pylori diagnostics market. Various entities, including governments, healthcare institutions, and advocacy groups, have been proactively advocating for public awareness initiatives to inform people about the possible outcomes of untreated infections. This heightened awareness has encouraged individuals to pursue screening and diagnostic services, thereby amplifying the demand for H. pylori testing. Healthcare providers and public health organizations have initiated screening programs to identify and treat H. pylori infections at an early stage. A recent survey revealed that approximately 80.1% of respondents were aware of H. pylori, yet 85.7% believed that the infection often resolves on its own. Also, 51.2% were unaware that H. pylori can be transmitted between family members, while 28.2% expressed neutrality on this matter. These programs are especially prevalent in regions with high infection rates, such as Asia, South America, and parts of Europe. In many cases, H. pylori screening is integrated into routine healthcare check-ups, ensuring that individuals are tested and treated as needed. This approach has been vital in reducing the incidence of complications associated with H. pylori infections. The treatment of H. pylori is increasingly moving towards precision medicine. Emerging therapies, such as rifabutin triple therapy and PCAB-amoxicillin dual therapy, present viable alternatives to conventional treatment regimens. Additionally, the guidelines highlight the importance of antibiotic susceptibility testing to tailor treatments to individual patients, thereby enhancing eradication rates.

The global Helicobacter pylori diagnostics market has also benefitted from advancements in diagnostic technologies. Traditional methods of detecting H. pylori, such as serology and urea breath tests, have been supplemented by more accurate and efficient methods, including polymerase chain reaction (PCR) and next-generation sequencing (NGS). These technologies enable quicker and more precise diagnosis, leading to better treatment outcomes. Eradicating H. pylori infections can prevent the development of serious gastrointestinal conditions, including ulcers and gastric cancer. As awareness and screening programs have become more effective, the demand for H. pylori diagnostic tests has surged. The rapid identification of H. pylori allows for prompt antibiotic therapy and monitoring of treatment effectiveness, improving patient outcomes and reducing healthcare costs associated with treating complications.

The global Helicobacter pylori diagnostics market has experienced significant growth due to these factors. This growth extends to various segments of the market, including diagnostic tests, endoscopy equipment, and therapeutic regimens. As governments and healthcare providers continue to invest in H. pylori screening programs and the development of more accurate diagnostic tools, the market is expected to expand further. The impact of increased awareness and screening programs is not limited to a specific region. While H. pylori infections are more common in certain parts of the world, the global nature of this bacterium means that efforts to combat it are universal. The ripple effect of reducing H. pylori-related complications is felt in lower healthcare costs, improved quality of life for affected individuals, and a reduced burden on healthcare systems worldwide.

Download Free Sample Report

Key Market Challenges

Asymptomatic Carriers and the Need for Widespread Screening

One of the major challenges in the H. pylori diagnostics market is the prevalence of asymptomatic carriers. Many individuals can carry the bacterium without displaying any symptoms, making it difficult to identify them without widespread screening programs. These carriers can unknowingly transmit the infection to others, complicating efforts to control the spread of H. pylori.

Limited Public Awareness

Lack of awareness about H. pylori infection remains a significant issue, particularly in developing countries. Public knowledge about the bacterium, its potential health risks, and the importance of early detection is limited. This lack of awareness impedes efforts to increase demand for diagnostic tests.

Cost and Accessibility

Access to H. pylori diagnostic tests can be a challenge, particularly in low- and middle-income countries. The cost of diagnostic tests, especially the more advanced methods like polymerase chain reaction (PCR) and serology, can be prohibitive for many patients and healthcare systems. The lack of access to affordable diagnostics can delay the early detection and treatment of H. pylori infection.

Variability in Diagnostic Methods

The availability of various diagnostic methods for H. pylori can lead to inconsistent results. These methods include serology, urea breath tests, stool antigen tests, and endoscopy with biopsy. The variability in test results can create confusion among healthcare providers and patients, making it challenging to determine the most appropriate course of treatment.

Antibiotic Resistance

H. pylori is becoming increasingly resistant to antibiotics, which is a growing concern in the medical community. This resistance can complicate treatment regimens and may require additional diagnostic testing to determine the most effective antibiotics to use. These resistance issues may necessitate more advanced diagnostic methods to guide therapy effectively.

Sampling and Testing Challenges

Obtaining a representative sample for H. pylori testing can be challenging, especially when using invasive methods like endoscopy with biopsy. Sampling errors can lead to false negatives, causing delays in diagnosis and treatment. Non-invasive tests like urea breath tests and stool antigen tests can also produce false positives or negatives due to various factors, including patient compliance and the presence of other infections.

Cross-Reactivity with Other Pathogens

Some diagnostic tests for H. pylori may cross-react with other pathogens or substances, leading to inaccurate results. This can create confusion and unnecessary treatment, further emphasizing the need for more specific and reliable diagnostic tools.

Key Market Trends

Technological Advancements

Technological advancements are revolutionizing the healthcare industry, with a particular impact on diagnostics. One notable area where these innovations are making a significant difference is in the diagnosis of Helicobacter pylori (H. pylori) infections. H. pylori is a bacterium that infects the stomach lining and is a common cause of various gastrointestinal diseases, including gastritis and peptic ulcers.

The development of non-invasive diagnostic tests has been a game-changer in the H. pylori diagnostics market. These tests include breath tests and stool antigen tests. Breath tests, such as the urea breath test, are simple and painless, involving the patient breathing into a device that measures the presence of specific compounds produced by H. pylori. Similarly, stool antigen tests detect H. pylori proteins in stool samples. These non-invasive methods are not only more patient-friendly but also highly accurate. Technological advancements in molecular biology have enabled the development of highly sensitive and specific tests for H. pylori. Polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) allow for the detection of H. pylori DNA, offering rapid and precise results. These methods are particularly useful in cases where conventional tests may yield false negatives. Serological tests, which detect the presence of antibodies against H. pylori in the blood, have also seen improvements in accuracy and specificity. Technological innovations in this area have made it easier to differentiate current infections from past exposure, helping clinicians make more informed decisions about treatment. Advances in microfluidics and portable diagnostic devices have led to the development of rapid H. pylori diagnostic tests that can be conducted at the point of care. These POCTs provide real-time results, enabling faster decision-making and reducing the time between diagnosis and treatment initiation.

Segmental Insights

Technology  Insights

Based on the category of Technology, Immunoassays emerged as the dominant player in the global market for Helicobacter Pylori Diagnostics in 2024. Immunoassays are a diverse group of diagnostic techniques designed to measure specific antigens (proteins) or antibodies in biological samples. They play a pivotal role in the detection of H. pylori infection by identifying the presence of H. pylori-specific antigens or antibodies in patient samples, such as blood, serum, or stool. Immunoassays are highly accurate and specific, minimizing the chances of false-positive or false-negative results. The use of specific antibodies or antigens ensures that the test correctly identifies the presence or absence of H. pylori. Immunoassays are sensitive enough to detect even low levels of H. pylori antigens or antibodies, making them suitable for early diagnosis and monitoring of infections. Many immunoassays, particularly lateral flow assays, provide rapid results, enabling healthcare providers to make prompt treatment decisions. Immunoassays are generally non-invasive, as they require minimal patient discomfort compared to endoscopy or biopsy methods. This makes them more patient-friendly. Immunoassays are cost-effective, particularly lateral flow assays, which are often less expensive than other diagnostic methods like PCR or endoscopy. Immunoassays are widely accessible and can be used in various healthcare settings, including primary care, clinics, and even at-home test kits.

Type Insights

The Reagents segment is projected to experience rapid growth during the forecast period. Reagent-based diagnostic tests have demonstrated exceptional accuracy and sensitivity in detecting H. pylori infections. They can identify even low levels of the bacterium, which is crucial for both initial diagnosis and monitoring treatment progress. Reagent-based tests, including serology and stool antigen tests, are non-invasive, making them more patient-friendly. Unlike invasive methods like endoscopy, these tests don't require tissue sampling, which can be uncomfortable and carry certain risks. Reagent-based diagnostics tend to be more cost-effective than traditional methods, which involve expensive equipment and skilled medical personnel. This affordability makes it easier to conduct large-scale screening and testing programs. Reagent-based tests provide quicker results, often within hours, allowing healthcare providers to initiate treatment promptly, if necessary, and reducing patient anxiety. The simplicity of reagent-based tests has made them accessible even in remote or resource-limited areas, improving the reach of Helicobacter pylori diagnostics.

Download Free Sample Report

Regional Insights

North America emerged as the dominant in the global Helicobacter Pylori Diagnostics market in 2024, holding the largest market share in terms of value. One of the primary reasons for North America's dominance in the H. pylori diagnostics market is the region's cutting-edge technological advancements in the field of medical diagnostics. The United States and Canada are home to many innovative diagnostic companies, research institutions, and medical professionals. These entities have pioneered the development of highly sensitive and specific diagnostic tests for H. pylori, enabling early detection and better patient outcomes. Advanced diagnostic tools, such as polymerase chain reaction (PCR), serology, and urea breath tests, have been developed and perfected in North America. These techniques provide accurate results and have become the gold standard for H. pylori detection. This technological prowess gives North America a competitive edge in the global market. North America boasts a robust and efficient healthcare infrastructure, which is essential for the successful management and diagnosis of H. pylori infections. This region is known for its well-established healthcare system, including state-of-the-art laboratories, skilled medical professionals, and a vast network of healthcare facilities. The seamless integration of diagnostic services into the existing healthcare system has played a pivotal role in the region's market dominance. In addition, the availability of diagnostic tests across a wide range of healthcare settings, from primary care clinics to specialized gastroenterology centers, ensures that individuals are tested and diagnosed promptly, reducing the overall burden of H. pylori-related diseases.

Recent Developments

• In December 2024, A team of Indian scientists, including researchers from CSIR-Institute of Genomics and Integrative Biology (IGIB) and AIIMS, has developed an innovative CRISPR-based diagnostic test, FELUDA, for the detection of H. pylori bacteria. This new method represents a significant advancement in diagnostic technology, offering a more precise and efficient way to identify H. pylori infections.
• In November 2024, Experts emphasize the need for improved diagnostic protocols and further research to address the growing challenge of H. pylori infection in India. The bacterial infection, which typically starts in childhood, is nearly ten times more prevalent than diabetes and is a leading cause of chronic gastritis, peptic ulcers, and even stomach cancer. Health professionals stress the urgency of advancing detection methods and treatment options to effectively combat the widespread impact of this condition in the country.
• In November 2024, AIG Hospitals has launched the Barry Marshall Centre in Hyderabad, dedicated to researching H. pylori infections and their treatment. The Centre aims to develop advanced diagnostic protocols, with a focus on individuals over the age of 50 who experience persistent stomach pain or digestive issues, enhancing early detection and management of these conditions.
• In September 2024, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that its low-dose rifabutin-triple therapy, Talicia, has been included as an empirically prescribed first-line treatment option for Helicobacter pylori (H. pylori) infection in the recently published American College of Gastroenterology (ACG) Clinical Guideline. This recognition underscores Talicia's position as a preferred therapeutic choice for managing H. pylori infections.
• In August 2024, MP Biomedicals has launched a new line of in vitro diagnostic tests utilizing immunochromatographic technology to detect key gastrointestinal pathogens. The new diagnostic kits target Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. These advanced tools are designed to deliver rapid, accurate results, empowering healthcare professionals to quickly identify and manage gastrointestinal infections more effectively.
• In December 2023, Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic products, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Hp Detect™ Stool Antigen ELISA test (K232892). This innovative product is designed to detect the presence of H. pylori bacteria, which affects approximately 35% of the U.S. population and is a leading cause of gastric diseases worldwide, with an estimated global prevalence of 50%.
• In July 2023, Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has granted clearance for Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stool samples. This new product addition strengthens Meridian's comprehensive H. pylori portfolio, which already includes BreathID® (urea breath test for H. pylori), Curian® HpSA (fluorescent immuno analyzer antigen test), and ImmunoCard® Stat! HpSA (rapid colorimetric antigen test).
• In October 2022, Gulf Medical University's College of Medicine conducted an awareness campaign focused on H. pylori and associated stomach conditions.
• In May 2022, Biomerica, a company specializing in biomedical technology, introduced the CE Mark for hp+detect, a diagnostic test designed to identify the presence of H. pylori bacteria.
• In April 2021, Otsuka Pharmaceutical Corporation, Ltd. introduced QuickNavi, a rapid H. pylori detection kit that delivers test results within just eight minutes.

Key Market Players

• Thermo Fisher Scientific inc.
• Biohit Oyj
• Quest Diagnostics Incorporated
• Meridian Bioscience
• Bio-Rad Laboratories
• Alpha Laboratories Ltd
• F. Hoffmann-La Roche Ltd
• Coris BioConcept
• Certest Biotec
• Epitope Diagnostics, Inc.

Report Scope:

In this report, the Global Helicobacter Pylori Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Helicobacter Pylori Diagnostics Market, By Type:

o   Instruments

o   Reagents

o   Services

• Helicobacter Pylori Diagnostics Market, By Technology:

o   Immunoassays

o   POC

o   Molecular Diagnostics

• Helicobacter Pylori Diagnostics Market, By End user:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Helicobacter Pylori Diagnostics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Helicobacter Pylori Diagnostics Market.

Available Customizations:

Global Helicobacter Pylori Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Helicobacter Pylori Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]